News

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its…

1 year ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

1 year ago

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of DirectorsSINGAPORE and NORTH BRUNSWICK, N.J.…

1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC…

1 year ago

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage…

1 year ago

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position…

1 year ago

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…

1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet…

1 year ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in…

1 year ago

Ocuphire Pharma to Present at Two Investor Conferences in August

FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

1 year ago